Gene therapies advance towards finish line

Nature Reviews Drug Discovery 10, 719-720 (October 2011) | doi:10.1038/nrd3572

Asher Mullard

News and Analysis. Over a decade since gene therapy development came to a near standstill with the death of a clinical trial participant, the field is overcoming issues of immunogenicity, carcinogenicity, manufacturing and small patient populations.....

“I am certain that a gene therapy is going to cross the finish line within the next year or two, in either the United States or the European Union,” says Coté.